P&T Committees Would Be Powerful Force Under Medicare Rx
Executive Summary
The recommendations of pharmacy & therapeutics committees would be binding on Medicare prescription drug plans under the proposed implementing regulations for the Part D benefit
You may also be interested in...
Regulating Formularies: OIG Wants Closer Scrutiny of Process; CMS Says Focus on Results
The HHS Inspector General is concerned about lax oversight of conflict-of-interest standards on formulary committees for Medicare Part D plans. CMS is defending its approach, which emphasizes review of the formularies themselves, rather than the process to construct them. For biopharma companies, the “right” regulatory model for formulary oversight is an important issue as health care reform evolves.
P&T Cmtes. Need Incentives To Use Cost-Effectiveness Analyses – MedPAC
Medicare prescription drug plan pharmacy & therapeutics committees should be given incentives for using cost-effectiveness analyses to develop formularies, Medicare Payment Advisory Commission member Alan Nelson suggested during a March 12 meeting in Washington D.C
P&T Cmtes. Need Incentives To Use Cost-Effectiveness Analyses – MedPAC
Medicare prescription drug plan pharmacy & therapeutics committees should be given incentives for using cost-effectiveness analyses to develop formularies, Medicare Payment Advisory Commission member Alan Nelson suggested during a March 12 meeting in Washington D.C